Business
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webc
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":130,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ttP74diEks8HOrImNeTk.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e","width":130,"height":33}},"lazy":false},{"type":"text","content":"Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients)","length":185,"tagName":"p"},{"type":"text","content":"The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026","length":167,"tagName":"p"},{"type":"text","content":"Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients)","length":121,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Today at 4:30 PM ET","length":47,"tagName":"p"},{"type":"text","content":"CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for central nervous system and oncology indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate and pipeline update.","length":369,"tagName":"p"},{"type":"text","content":"“2025 is off to an outstanding start for Relmada,” said Sergio Traversa, CEO of Relmada. “With the addition of NDV-01 and sepranolone, two differentiated Phase 2 product candidates targeting large, underserved markets, we’ve significantly enhanced our pipeline and long-term value proposition. The recently announced proof-of-concept data for NDV-01 presented at AUA 2025 reinforce its potential to become a best-in-class, bladder-sparing treatment for non-muscle invasive bladder cancer (NMIBC).”","length":507,"tagName":"p"},{"type":"text","content":"“Our strategic focus remains on developing a diverse pipeline with strong scientific rationale, intellectual ...